AI주식인사이트AI Stock Insight
B

바이오노트

377740KOSPI

55.0 / 100

Reference Date: 2026-10-23

Financial Score24.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 2.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

BIONOTE is a company established in 2003 specializing in animal diagnostic products and bio-content, leveraging its proprietary recombinant antigen and antibody technology to develop and manufacture rapid immunodiagnostic, enzyme-linked immunosorbent assay (ELISA), and related products. Key offerings include the BIONOTE Rapid and Vcheck F brands, used in veterinary clinics and farms, with expansion into human in vitro diagnostic (IVD) raw material supply.

Number of Employees

334people

Average Salary

49.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.31Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
-5.56Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
2.09Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.6% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲81.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 4,580Won52-week high 6,23052-week low 4,365
1-month return2.0Point

1m -2.76% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral기업가치제고계획(자율공시) (PBR 개선 계획 제출 기업)2026-10-22